SCHEMBL24310130

SCHEMBL24310130

Cc1ccccc1Oc1nc(NS(=O)(=O)c2cnn(C)c2)nc(Cl)c1C(F)(F)C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 7/20 0.36
▸ HTR7 P34969 7/20 0.36
▸ DRD2 P14416 2/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ THRB P10828 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ SLC22A12 Q96S37 1/20 0.33
▸ MAP3K7 O43318 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ MAP2K1 Q02750 1/20 0.32
▸ KAT6A Q92794 1/20 0.31
▸ KAT5 Q92993 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ KMT2A Q03164 3/20 0.31
▸ MEN1 O00255 2/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ HTR2A P28223 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566383 1.00 HTR1A (0.36) HTR1AHTR7DRD2HTR6THRB
SCHEMBL24309646 0.93 HTR1A (0.37) HTR1AHTR7DRD2HTR6THRB
SCHEMBL29566971 0.93 HTR1A (0.37) HTR1AHTR7DRD2HTR6THRB
SCHEMBL24310083 0.88 HTR1A (0.39) HTR1AHTR7DRD2HTR6THRB
SCHEMBL26811975 0.88 HTR1A (0.35) HTR1AHTR7DRD2HTR6THRB
SCHEMBL24309427 0.84 HTR1A (0.40) HTR1AHTR7DRD2HTR6THRB
SCHEMBL29567055 0.84 HTR1A (0.40) HTR1AHTR7DRD2HTR6THRB
SCHEMBL24309502 0.84 HTR1A (0.35) HTR1AHTR7KAT6AKAT5TSHR
SCHEMBL29566783 0.83 HTR6 (0.34) HTR1AHTR7DRD2HTR6KMT2A
SCHEMBL24309538 0.83 HTR6 (0.34) HTR1AHTR7DRD2HTR6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B HTR1A 4018/4885HTR7 3833/4885DRD2 4505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback